TURKDERM-TURKISH ARCHIVES OF DERMATOLOGY AND VENEROLOGY, cilt.44, sa.1, ss.19-24, 2010 (SCI-Expanded)
Background and Design: Efalizumab is a recombinant, humanized IgG1 monoclonal antibody used in the treatment of moderate to severe plaque psoriasis. Recently, because of the cases of progressive multifocal leukoencephalopathy, the marketing authorisation for efalizumab is suspended. This study is designed to examine the problems that we have faced in our patients that had to discontinue efalizumab and their responses to transition treatments.